Literature DB >> 23593937

Interplay between coagulation and vascular inflammation in sickle cell disease.

Erica Sparkenbaugh1, Rafal Pawlinski.   

Abstract

Sickle cell disease is the most common inherited haematological disorder that leads to the irreversible damage of multiple organs. Although sickling of red blood cells and vaso-occlusion are central to the pathophysiology of sickle cell disease, the importance of haemolytic anaemia and vasculopathy has been recently recognized. A hypercoagulable state is another prominent feature of sickle cell disease and is mediated by activation of both intrinsic and extrinsic coagulation pathways. Growing evidence demonstrates that coagulation may not only contribute to the thrombotic complications, but also to vascular inflammation associated with this disease. This article summarizes the role of vascular inflammation and coagulation activation, discusses potential mechanisms responsible for activation of coagulation and reviews recent data demonstrating the crosstalk between coagulation and vascular inflammation in sickle cell disease.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23593937      PMCID: PMC3878906          DOI: 10.1111/bjh.12336

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  145 in total

1.  Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa.

Authors:  P E J Van Der Meijden; M Van Schilfgaarde; R Van Oerle; T Renné; H ten Cate; H M H Spronk
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

2.  Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?

Authors:  H J Wolters; H ten Cate; L L Thomas; D P Brandjes; A van der Ende; Y van der Heiden; L W Statius van Eps
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

3.  Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia.

Authors:  M P Colella; E V De Paula; N Conran; J A Machado-Neto; J M Annicchino-Bizzacchi; F F Costa; S T O Saad; F Traina
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

4.  Tissue factor expression by endothelial cells in sickle cell anemia.

Authors:  A Solovey; L Gui; N S Key; R P Hebbel
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

5.  Pulmonary changes in sickle cell disease.

Authors:  E H Oppenheimer; J R Esterly
Journal:  Am Rev Respir Dis       Date:  1971-06

6.  Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises.

Authors:  R Cabannes; J Lonsdorfer; J P Castaigne; A Ondo; A Plassard; I Zohoun
Journal:  Agents Actions Suppl       Date:  1984

Review 7.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

8.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

9.  Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13.

Authors:  Junmei Chen; Xiaoyun Fu; Yi Wang; Minhua Ling; Brad McMullen; John Kulman; Dominic W Chung; José A López
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

10.  Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises.

Authors:  H Chaplin; M C Monroe; A C Malecek; L K Morgan; J Michael; W A Murphy
Journal:  East Afr Med J       Date:  1989-09
View more
  56 in total

Review 1.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

2.  Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Authors:  Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

3.  Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease.

Authors:  Brian T Kalish; Alessandro Matte; Immacolata Andolfo; Achille Iolascon; Olga Weinberg; Alessandra Ghigo; James Cimino; Angela Siciliano; Emilio Hirsch; Enrica Federti; Mark Puder; Carlo Brugnara; Lucia De Franceschi
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

4.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

5.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2016-10

Review 6.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

Review 7.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 8.  Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation.

Authors:  Florian Langer; Wolfram Ruf
Journal:  Thromb Haemost       Date:  2014-01-23       Impact factor: 5.249

9.  Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.

Authors:  Patricia M Fortin; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2018-08-01

10.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.